Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies

Pigment Cell and Melanoma Research

Volumn 25, Issue 6, 2012, Pages 819-831

  Bagrodia, Shubha ^a   Smeal, Tod ^a   Abraham, Robert T ^a  

^a PFIZER INC   (United States)

Author keywords

Drug resistance; Kinase inhibitors; Oncogenic drivers

Indexed keywords

2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; AFATINIB; AP 26113; CH 5424802; CRIZOTINIB; DABRAFENIB; DACARBAZINE; DACOMITINIB; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GANITUMAB; GEFITINIB; IMATINIB; LDK 378; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NERATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RILOTUMUMAB; SELUMETINIB; SUNITINIB; T 790M; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; XL 888;

APOPTOSIS; BRAIN METASTASIS; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CROSS RESISTANCE; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG TARGETING; EPIGENETICS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; KERATOACANTHOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE K RAS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; RASH; REVIEW; SKIN CARCINOMA; SKIN DEFECT; SOLID TUMOR;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84867909730     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12007     Document Type: Review

References (110)

1. Amado, R.G., Wolf, M., Peeters, M. et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634.
2. Arrondeau, J., Mir, O., Boudou-Rouquette, P., Coriat, R., Ropert, S., Dumas, G., Rodrigues, M.J., Rousseau, B., Blanchet, B., and Goldwasser, F. (2011). Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest. New Drugs DOI: 10.1007/s10637-011-9764-8 [Epub ahead of print].
3. Azam, M., Seeliger, M.A., Gray, N.S., Kuriyan, J., and Daley, G.Q. (2008). Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 15, 1109-1118.
4. Bell, R.E., and Levy, C. (2011). The three M's: melanoma, microphthalmia-associated transcription factor and microRNA. Pigment Cell Melanoma Res. 24, 1088-1106.
5. Bell, D.W., Gore, I., Okimoto, R.A. et al. (2005). Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 37, 1315-1316.
6. Benedettini, E., Sholl, L.M., Peyton, M. et al. (2010). Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol. 177, 415-423.
7. Bollag, G., Hirth, P., Tsai, J. et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599.
8. Chaft, J.E., Arcila, M.E., Paik, P.K. et al. (2012). Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol. Cancer Ther. 11, 485-491.
9. Chakrabarty, A., Sanchez, V., Kuba, M.G., Rinehart, C., and Arteaga, C.L. (2012). Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. U S A 109, 2718-2723.
10. Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P.K., Baselga, J., and Rosen, N. (2011). AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71.
11. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
12. Choi, Y.L., Soda, M., Yamashita, Y. et al. (2010). EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739.
13. Christensen, J.G., Zou, H.Y., Arango, M.E., Li, Q., Lee, J.H., Mcdonnell, S.R., Yamazaki, S., Alton, G.R., Mroczkowski, B., and Los, G. (2007). Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314-3322.
14. Corcoran, R.B., Dias-Santagata, D., Bergethon, K., Iafrate, A.J., Settleman, J., and Engelman, J.A. (2010). BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal 3, ra84.
15. Costa, D.B., Halmos, B., Kumar, A., Schumer, S.T., Huberman, M.S., Boggon, T.J., Tenen, D.G., and Kobayashi, S. (2007). BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4, 1669-1679; discussion 1680.
16. Davies, M.A. (2012). The role of the PI3K-AKT pathway in melanoma. Cancer J. 18, 142-147.
17. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
18. Davis, M.I., Hunt, J.P., Herrgard, S., Ciceri, P., Wodicka, L.M., Pallares, G., Hocker, M., Treiber, D.K., and Zarrinkar, P.P. (2011). Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051.
19. Diaz, L.A. Jr, Williams, R.T., Wu, J. et al. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-40.
20. Dienstmann, R., Brana, I., Rodon, J., and Tabernero, J. (2011). Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 16, 1729-1740.
21. Doebele, R.C., Pilling, A.B., Aisner, D.L. et al. (2012). Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472-1482.
22. Duncan, J.S., Whittle, M.C., Nakamura, K. et al. (2012). Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321.
23. Engelman, J.A. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562.
24. Engelman, J.A., Zejnullahu, K., Gale, C.M. et al. (2007). PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67, 11924-11932.
25. Faber, A., Corcoran, R.B., Ebi, H. et al. (2011). BIM expression in treatment naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 1, 352-365.
26. Falchook, G.S., Long, G.V., Kurzrock, R. et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
27. Felsher, D.W., and Bishop, J.M. (1999). Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199-207.
28. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
29. Flaherty, K.T., Hodi, F.S., and Fisher, D.E. (2012). From genes to drugs: targeted strategies for melanoma. Nat. Rev. Cancer 12, 349-361.
30. Garofalo, M., Romano, G., Di Leva, G. et al. (2012). EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 18, 74-82.
31. Ghislin, S., Deshayes, F., Middendorp, S., Boggetto, N., and Alcaide-Loridan, C. (2012). PHF19 and Akt control the switch between proliferative and invasive states in melanoma. Cell Cycle 11, 1634-1645.
32. Godin-Heymann, N., Ulkus, L., Brannigan, B.W., Mcdermott, U., Lamb, J., Maheswaran, S., Settleman, J., and Haber, D.A. (2008). The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther. 7, 874-879.
33. Greger, J.G., Eastman, S.D., Zhang, V., Bleam, M.R., Hughes, A.M., Smitheman, K.N., Dickerson, S.H., Laquerre, S.G., Liu, L., and Gilmer, T.M. (2012). Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11, 909-920.
34. Hatzivassiliou, G., Song, K., Yen, I. et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435.
35. Heidorn, S.J., Milagre, C., Whittaker, S. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221.
36. Hodi, F.S., O'day, S.J., Mcdermott, D.F. et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
37. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
38. Hoek, K.S., and Goding, C.R. (2010). Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 23, 746-759.
39. Janne, P.A., Gray, N., and Settleman, J. (2009). Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709-723.
40. Johannessen, C.M., Boehm, J.S., Kim, S.Y. et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
41. Katayama, R., Shaw, A.T., Khan, T.M. et al. (2012). Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci. Transl. Med. 4, 120ra17.
42. Kobayashi, S., Ji, H., Yuza, Y., Meyerson, M., Wong, K.K., Tenen, D.G., and Halmos, B. (2005). An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65, 7096-7101.
43. Kopetz, S., Desai, S., Chan, E., Hecht, J.R., O'dwyer, P.J., Lee, R.J., Nolop, K.B., and Saltz, L. (2010). PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28, 15s, 2010 (suppl; abstr 3534).
44. Kornev, A.P., Haste, N.M., Taylor, S.S., and Eyck, L.F. (2006). Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. U S A 103, 17783-17788.
45. Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., and Mitsudomi, T. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12, 5764-5769.
46. Koya, R.C., Mok, S., Otte, N. et al. (2012). BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 72, 3928-3937.
47. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
48. Kwak, E.L., Sordella, R., Bell, D.W. et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. U S A 102, 7665-7670.
49. Kwak, E.L., Bang, Y.J., Camidge, D.R. et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703.
50. Lamming, D.W., Ye, L., Katajisto, P. et al. (2012). Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335, 1638-1643.
51. Lee, J.T., Li, L., Brafford, P.A. et al. (2010). PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res. 23, 820-827.
52. Lemmon, M.A., and Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134.
53. Little, A.S., Smith, P.D., and Cook, S.J. (2012). Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene DOI: 10.1038/onc.2012.160 [Epub ahead of print].
54. Misale, S., Yaeger, R., Hobor, S. et al. (2012). Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536.
55. Muranen, T., Selfors, L.M., Worster, D.T., Iwanicki, M.P., Song, L., Morales, F.C., Gao, S., Mills, G.B., and Brugge, J.S. (2012). Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21, 227-239.
56. Nathanson, K.L., Martin, A., Letrero, R. et al. (2011). Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). Int. J. Clin. Oncol. 29, (suppl; abstr 8501).
57. Nazarian, R., Shi, H., Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
58. Ng, K.P., Hillmer, A.M., Chuah, C.T. et al. (2012). A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 18, 521-528.
59. Oberholzer, P.A., Kee, D., Dziunycz, P. et al. (2012). RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30, 316-321.
60. O'Reilly, K.E., Rojo, F., She, Q.B. et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508.
61. Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., Kris, M.G., and Varmus, H. (2005a). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73.
62. Pao, W., Wang, T.Y., Riely, G.J., Miller, V.A., Pan, Q., Ladanyi, M., Zakowski, M.F., Heelan, R.T., Kris, M.G., and Varmus, H.E. (2005b). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17.
63. Paraiso, K.H., Xiang, Y., Rebecca, V.W. et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760.
64. Paraiso, K.H., Haarberg, H.E., Wood, E. et al. (2012). The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin. Cancer Res. 18, 2502-2514.
65. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., and Rosen, N. (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430.
66. Poulikakos, P.I., Persaud, Y., Janakiraman, M. et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-90.
67. Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A., and Bernards, R. (2012). Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103.
68. Qi, J., Mctigue, M.A., Rogers, A., Lifshits, E., Christensen, J.G., Janne, P.A., and Engelman, J.A. (2011). Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 71, 1081-1091.
69. Regales, L., Gong, Y., Shen, R. et al. (2009). Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000-3010.
70. Robert, C., Thomas, L., Bondarenko, I. et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526.
71. Rodrik-Outmezguine, V.S., Chandarlapaty, S., Pagano, N.C., Poulikakos, P.I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., and Rosen, N. (2011). mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 1, 248-259.
72. Sasaki, T., Koivunen, J., Ogino, A. et al. (2011). A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71, 6051-6060.
73. Sawyers, C.L. (2008). The cancer biomarker problem. Nature 452, 548-552.
74. Sharma, S.V., Fischbach, M.A., Haber, D.A., and Settleman, J. (2006) "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 12, 4392s-4395s.
75. Sharma, S.V., Lee, D.Y., Li, B. et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80.
76. Shaw, A.T., Yeap, B.Y., Solomon, B.J. et al. (2011). Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012.
77. Shi, Y., Yan, H., Frost, P., Gera, J., and Lichtenstein, A. (2005). Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 4, 1533-1540.
78. Shi, H., Kong, X., Ribas, A., and Lo, R.S. (2011). Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 71, 5067-5074.
79. Shi, H., Moriceau, G., Kong, X. et al. (2012a). Preexisting MEK1 Exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2, 414-424.
80. Shi, H., Moriceau, G., Kong, X. et al. (2012b). Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724.
81. Shih, J.Y., Gow, C.H., Yu, C.J., Yang, C.H., Chang, Y.L., Tsai, M.F., Hsu, Y.C., Chen, K.Y., Su, W.P., and Yang, P.C. (2006). Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int. J. Cancer 118, 963-969.
82. Sjoblom, T., Jones, S., Wood, L.D. et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274.
83. Smalley, K.S., Lioni, M., Dalla Palma, M. et al. (2008). Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 7, 2876-2883.
84. Soda, M., Choi, Y.L., Enomoto, M. et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566.
85. Sos, M.L., Koker, M., Weir, B.A. et al. (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69, 3256-3261.
86. Sosman, J.A., Kim, K.B., Schuchter, L. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
87. Stegmeier, F., Warmuth, M., Sellers, W.R., and Dorsch, M. (2010). Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin. Pharmacol. Ther. 87, 543-552.
88. Straussman, R., Morikawa, T., Shee, K. et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504. doi: 10.1038/nature11183.
89. Su, F., Viros, A., Milagre, C. et al. (2012a). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215.
90. Su, K.Y., Chen, H.Y., Li, K.C. et al. (2012b). Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30, 433-440.
91. Sumimoto, H., Imabayashi, F., Iwata, T., and Kawakami, Y. (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651-1656.
92. Sun, S.Y., Rosenberg, L.M., Wang, X., Zhou, Z., Yue, P., Fu, H., and Khuri, F.R. (2005). Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052-7058.
93. Tenbaum, S.P., Ordonez-Moran, P., Puig, I. et al. (2012). beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat. Med. 18, 892-901.
94. Thoreen, C.C., Kang, S.A., Chang, J.W., Liu, Q., Zhang, J., Gao, Y., Reichling, L.J., Sim, T., Sabatini, D.M., and Gray, N.S. (2009). An ATP-competitive mTOR inhibitor reveals rapamycin-insensitive functions of mTORC1. J. Biol. Chem. 284, 8023-8032.
95. Topalian, S.L., Hodi, F.S., Brahmer, J.R. et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
96. Torti, V.R., Wojciechowicz, D., Hu, W. et al. (2012). Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901. Mol. Cancer Ther. DOI: 10.1158/1535-7163 [Epub ahead of print].
97. Turke, A.B., Zejnullahu, K., Wu, Y.L. et al. (2010). Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88.
98. Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
99. Wagle, N., Emery, C., Berger, M.F. et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096.
100. Weber, J.S., Flaherty, K.T., Infante, J.R. et al. (2012). Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. J. Clin. Oncol. 30, (suppl; abstr 8510).
101. Weinstein, I.B. (2002). Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63-64.
102. Wilmott, J.S., Long, G.V., Howle, J.R., Haydu, L.E., Sharma, R.N., Thompson, J.F., Kefford, R.F., Hersey, P., and Scolyer, R.A. (2012). Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386-1394.
103. Wilson, T.F., Fridlyand, J., Yan, Y. et al. (2012). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509.
104. Wood, L.D., Parsons, D.W., Jones, S. et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113.
105. Xing, F., Persaud, Y., Pratilas, C.A. et al. (2012). Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31, 446-457.
106. Yamazaki, S., Skaptason, J., Romero, D., Lee, J.H., Zou, H.Y., Christensen, J.G., Koup, J.R., Smith, B.J., and Koudriakova, T. (2008). Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab. Dispos. 36, 1267-1274.
107. Yamazaki, S., Vicini, P., Shen, Z., Zou, H.Y., Lee, J., Li, Q., Christensen, J.G., Smith, B.J., and Shetty, B. (2012). Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J. Pharmacol. Exp. Ther. 340, 549-557.
108. Yang, H., Higgins, B., Kolinsky, K. et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527.
109. Zipser, M.C., Eichhoff, O.M., Widmer, D.S. et al. (2011). A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell Melanoma Res. 24, 326-333.
110. Zou, H.Y., Li, Q., Lee, J.H. et al. (2007). An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417.